Jump Financial LLC Buys 25,634 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Jump Financial LLC increased its stake in Regeneron Pharmaceuticals by 136.4%, acquiring an additional 25,634 shares to reach a total of 44,428 shares valued at $28.18 million.
• Regeneron Pharmaceuticals reported a Q2 EPS of $12.89, significantly exceeding estimates of $8.43, with revenues of $3.68 billion, marking a 3.6% year-over-year increase.
• The company recently announced a quarterly dividend of $0.88 per share, translating to an annualized yield of 0.6%, with a dividend payout ratio of 8.87%.

Jump Financial LLC raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 136.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,428 shares of the biopharmaceutical company's stock after buying an additional 25,634 shares during the quarter. Jump Financial LLC's holdings in Regeneron Pharmaceuticals were worth $28,178,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of REGN. Marietta Wealth Management LLC lifted its position in Regeneron Pharmaceuticals by 30.2% during the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock worth $6,836,000 after buying an additional 2,501 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Regeneron Pharmaceuticals by 3.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock worth $16,255,000 after buying an additional 955 shares during the period. KBC Group NV raised its holdings in Regeneron Pharmaceuticals by 9.4% during the 1st quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock worth $94,779,000 after buying an additional 12,793 shares during the period. Finally, Lmcg Investments LLC raised its holdings in Regeneron Pharmaceuticals by 231.3% during the 1st quarter. Lmcg Investments LLC now owns 14,481 shares of the biopharmaceutical company's stock worth $9,184,000 after buying an additional 10,110 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $589.48 on Friday. The business's 50 day moving average price is $550.48 and its 200 day moving average price is $592.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The company has a market cap of $62.48 billion, a price-to-earnings ratio of 14.86, a PEG ratio of 1.99 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm had revenue of $3,675,600 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same period in the previous year, the firm posted $11.56 EPS. Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Analysts Set New Price Targets

Several research firms recently weighed in on REGN. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Rothschild & Co Redburn assumed coverage on Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They set a "buy" rating and a $890.00 target price for the company. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. The Goldman Sachs Group reduced their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Finally, JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday, June 9th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $829.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.